Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltegravir + abacavir
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Raltegravir + abacavir is a combination of two antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV) infection. Raltegravir is an HIV integrase strand transfer inhibitor that blocks the integration of viral DNA into the host genome, thereby preventing viral replication[2][6]. Abacavir is a nucleoside analogue reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, blocking viral RNA from being converted into DNA and thus halting replication[4]. This combination is often used with lamivudine as part of highly active antiretroviral therapy regimens for adults living with HIV due to its high virological efficacy and good tolerability profile[5][8]. The primary indication for this drug combination is the management and suppression of HIV infection.
- Brand names
- Isentress (for raltegravir)Ziagen (for abacavir)
- Other names
- RAL (for raltegravir)ABC (for abacavir)
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on raltegravir + abacavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltegravir + abacavir.